BioTech/Drugs - Cambridge, MA, US
EdiGene is a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with serious genetic diseases and cancer across multiple modalities. The company has built three centers of excellence along gene editing, bioinformatics and high throughput genome-editing screening, and propels its pipeline on four therapeutic platforms: ex vivo gene-editing hematopoietic stem cell, ex vivo gene-editing T cells for allogeneic CAR-T, in vivo RNA base editing using LEAPERTM and high throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China, and Cambridge, Massachusetts, USA.
Ruby On Rails
Apache
Baidu Ads
Mobile Friendly